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1. Introduction 
Oligomycin is a potent inhibitor of mitochondrial 
ATPase activity when the enzyme is bound to the 
membranes orwhen it is solubilized from yeast as 
a multi-subunit complex by extraction with Triton 
X-100 [ 1,2] . In contrast, oligomycin has no effect 
on the soluble F1 ATPase which has been stripped 
of the most tightly associated membrane components 
of the complex [3]. We have recently established that 
oligomycin can be specifically bound to subunit 9 
(nomenclature of Tzagoloff and Meagher [4] ) of the 
enzyme complex by reductive alkylation [5] . This 
subunit is part of the ‘membrane sector’ of the 
ATPase complex and has a primary structure dominat- 
ed by amino acids with nonpolar side chains [6]. It 
is soluble in chloroform/methanol (2: 1) and is 
considered to be buried within the mitochondrial 
membrane structure. 
A large number of mutants of the yeast SaccharcF 
myces cerevisiae have now been reported that are 
resistant to oligomycin inhibition [7,8] . Most of 
these result from changes in mitochondrial DNA. The 
mitochondrial mutants have recently been divided 
into three classes based on mapping of genetic loci 
and on cross resistance with other inhibitors [8]. 
Mutants of Class B, but not Classes A or C appear to 
result in changes in subunit 9 of the ATPase. Mutants 
of this type thus allow analysis of the interaction of 
oligomycin with the enzyme [9]. 
Oligomycin has frequently been proposed to 
inhibit by blocking proton translocation across mito- 
chondrial membranes [lo] . Thus, its association with 
subunit 9 in the ATPase complex suggests hat this 
small proteolipid may somehow be involved as a 
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proton acceptor or with the movement of protons 
through the membrane. If this is the case, then it 
might be postulated that ionophoric substances may 
have a major effect on this function and that this 
may be examined by enzymic analysis of the oligo- 
mycin sensitive ATPase under appropriate conditions. 
The experiments reported here test this postulate 
and show that valinomycin can reverse oligomycin 
inhibition. This reversal is altered quantitatively by 
mutations causing modifications in subunit 9. 
Nigericin, but not CCCP has a similar effect in revers- 
ing the oligomycin block. 
2. Materials and methods 
The yeast strains used were D243-4A and a mito- 
chondrially inherited oligomycin resitant strain OR-4 
derived from D2434A [ 111. 
Cells were grown to early stationary phase in 1% 
Difco peptone, 1% yeast extract and 1% glucose. Cells 
were broken using a Braun homogenizer and mito- 
chondria were isolated as described previously [121. 
The mitochondria were lysed in 0.02 M Tris-HCl, 
0.01 M EDTA buffer, pH 7.8 and homogenized in a 
glass-Teflon homogenizer at a protein concentration 
of 25 mg/ml. Submitochondrial particles were prepar- 
ed by sonication [3] and Triton X-l 00 solubilized 
oligomycin sensitive ATPase was prepared by the 
method of Tzagoloff et al. [4] except hat the final 
step was chromatography on Sepharose 6B rather 
than glycerol-gradient centrifugation [S] . 
ATPase was assayed photometrically by coupling 
to pyruvate kinase and lactic dehydrogenase using the 
method of Monroy and Pullman [ 131. Inhibitors 
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were added as methanolic solutions. Oligomycin was 
obtained from Calbiochem, valinomycin from Sigma 
and nigericin was a gift from Dr I. H. Segel. Vent- 
uricidin was a gift from Dr A. W. Linnane. Phospho- 
enolpyruvate, pyruvate kinase, lactic dehydrogenase, 
ATP and NADH were purchased from Sigma Chemical 
Company. 
3. Results 
Inhibition of ATPase activities in lysed, homo- 
genized mitochondrial particles from strains D243-4A 
and the oligomycin resitant mutant OR4 prepared 
from this strain are illustrated in iig.1. It may also be 
seen in this figure that valinomycin has no measure- 
able effects on this activity at the concentration-range 
tested. However, when oligomycin concentration was 
maintained constant at a level which caused about 
90% inhibition of oligomycin sensitive ATPase while 
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Fig. 1. Reversal of oligomycin inhibition of mitochondrial Fig.2. Rate of ATPase reaction in the absence of oligomycin 
ATPase by valinomycin. The inhibition of D243-4A (-e-e-) (l), with 5 pg/ml oligomycin (4), with 5 &ml oligomycin 
and OR-4 (-.-.-) by oligomycin is shown. Valinomycin has plus 7.5 fig/ml valinomycin (2) and with 10 &ml oligomycin 
no inhibitory effect on ATPase activity (-o-o-). When oligo- plus 7.5 rg/ml valinomycin. The protein concentration of 
mycin concentration was held at 15 &ml and valinomycin lysed mitochondrial particles used in the assay was 0.75 
concentration was increased, the inhibition was reversed as mg/ml. The rate was measured by following the absorption 
shown by plotting activity against he ratio [valinomycin] / charge of NADH in the coupled enzyme assay procedure of 
[oligomycin] for strain D243-4A (-x-x-) and for OR-4 (-o-o-). Monroy and Pullman [ 131. 
valinomycin was added in increasing amounts, inhibi- 
tion due to oligomycin was reversed. This data is 
presented in fig.1 as ATPase activity versus [valino- 
mycin] / [oligomycin] ratio. For strain D243-4A the 
ratio giving 50% recovery of ATPase activity is close 
to one. When strain OR-4, which has a decreased 
binding constant for oligomycin, was examined under 
identical conditions, the midpoint for reversal of 
inhibition was found near a [valinomycin] /oligomycin] 
ratio of 0.33. 
While this method of analysis is convenient for 
comparing resistant and oligomycin sensitive strains, 
reversal of oligomycin inhibition by valinomycin is 
actually dependent upon the absolute concentration 
of valinomycin rather than on the ratio. This may be 
seen in tig.2, for example, in which the rate of ATPase 
reaction is followed in the presence of oligomycin at 
two different levels while maintaining valinomycin 
constant. The oligomycin and valinomycin do not 
appear to be competing for some common binding 
site on the enzyme. Addition of potassium ions to 
the lysed mitochondrial preparations was not neces- 
sary to obtain the valinomycin effect. However, in 
2.4.. 
Minutes 
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Fig.3. Reversal of oligomycin inhibition by nigericin. ATPase 
activity is shown as a function of oligomycin concentration 
(oligo), as a function of nigericin concentration (nig) and as 
a function of the nigericin/oligomycin ratio (N/O) with oligo- 
mycin held at a concentration of 10 pg/ml. 
the presence of 0.5 mM KC1 the ability of valinomycin 
to reverse inhibition was slightly enhanced. On the 
other hand, addition of 0.5 mM KC1 without valino- 
mycin causes increased oligomycin inhibition. 
Reversal of oligomycin inhibition by valinomycin 
is observed only in studies with mitochondrial 
particles. Preparations of Triton X-l 00 solubilized 
oligomycin sensitive ATPase, while strongly inhibited 
by oligomycin, are not subsequently reactivated by 
valinomycin. 
The ionophoric compound nigericin also reverses 
the oligomycin inhibition (fig.3). However, at higher 
concentrations, nigericin itself becomes inhibitory. 
The level of nigericin required for reversal is again 
considerably decreased in mitochondrial particles 
from strain OR-4 with altered ATPase subunit 9. 
Both valinomycin and nigericin have been reported 
to transport K’-ions and protons across membranes. 
The ionophore carboxyl cyanide m-chlorophenyl- 
hydrazone (CCCP), which is exclusively a proton 
transporter had no measurable effect on the level of 
oligomycin inhibition. 
fig venturicidin/mI 
Fig.4. Failure of vahnomycin to reverse venturicidin inhibition 
of ATPase activity..Venturicidin and valinomycin inhibition 
curves are shown as indicated on the figure. The activity in 
the presence of 10 rg/ml. venturicidin and varying levels of 
valinomycin is shown as the [valinomycin] /[venturicidin] 
ratio (Val/Ven). 
Venturicidin is an ATPase inhibitor with properties 
similar in many ways to oligomycin. A number of 
yeast mutants resistant to valinomycin are simul- 
taneously cross resistant to venturicidin. However, 
recent analyses have suggested that venturicidin acts 
at subunit 6 of the oligomycin sensitive ATPase 
complex rather than at subunit 9 [ 141. It can be 
seen in fig.4 that venturicidin inhibition of D243-4A 
cannot be reversed by valinomycin. 
4. Discussion 
The results of these experiments can most readily 
be fit into current hypotheses regarding the mode of 
action of the various inhibitors and ionophores by 
proposing first that oligomycin blocks ATPase activity 
by binding to subunit 9 directly. This inhibits activity 
by preventing proton translocation. The ionophores 
valinomycin or nigericin provide a mechanism for 
relieving this block, allowing an alternate pathway for 
ion transport. With this proposal, however, it is some- 
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what surprising that CCCP does not also reverse 
inhibition. The ability to bind K’ is apparently a
requirement in ionophores reversing the oligomycin 
block. Also, mutations of subunit 9 (Class B oligo- 
mycin resistant mutants) which cause a decreased 
sensitivity to oligomycin simultaneously decrease the 
levels of ionophores required to reverse the inhibition 
of ATPase. These latter results would suggest either 
some specific mode of interaction between the 
ionophores and subunit 9 or that the ionophoric 
activity takes place in a membrane nvironment with 
properties greatly influenced by the structure of 
subunit 9. Direct competition of ionophore for 
ollgomycin binding sites is ruled out by the experi- 
ments shown in figure 2 and intact membrane 
vesicles appear equired for reversing the inhibition. 
Thus, ionophoric activity occurring in the immediate 
vicinity of the ATPase subunit 9 protein and influenc- 
ed by its properties eems most likely. 
This conclusions i  somewhat at variance with the 
commonly postulated mode of function of valino- 
mycin as a general ionophore. However, it is difficult 
to rationalize the data presented here with a mechanism 
postulating no specific interaction with proteins of the 
ATPase system. Support for the conclusion that very 
specific interaction may be involved comes from the 
report of Griftiths [7] that cytoplasmically inherited 
valinomycin resistant mutants of yeast may be 
obtained. While further analysis of these mutants is 
required, the observed cytoplasmic inheritance makes 
it unlikely that these mutants result from permeability 
changes or enhanced etoxification reactions. 
The differences noted for ionophore effects in 
reversing oligomycin but not venturicidin inhibition 
give another indication that subunit 9 may be quite 
directly involved in some protonophoric function. 
Both these inhibitors act on the ‘membrane sector’ 
of oligomycin sensitive ATPase but not on the soluble 
F, -ATPase. Inhibition by venturicidin at subunit 6 
is not reversed by the ionophores, suggesting that this 
peptide is probably not involved directly with ion 
translocating functions. On the other hand, reversal 
of oligomycin inhibition at subunit 9 by a mechanism 
that probably does not displace the oligomycin but 
can substitute in ion-translocation does suggest this 
role for subunit 9 or a component attached to 
subunit 9. 
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